Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 8.49
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hindustan Bio Sciences Ltd. engages in the trade of pharmaceuticals and medical goods. Its product portfolio includes liquid injectables; liquid and dry syrups; eye, ear and nasal drops; pre-filled syringes; and non-sterile and sterile ointments; tablets; and capsules. The company was founded in 2000 and is headquartered in Hyderabad, India.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Data is available to registered users only
Buy
Sell